Damm Oliver, Horn Johannes, Mikolajczyk Rafael T, Kretzschmar Mirjam E E, Kaufmann Andreas M, Deleré Yvonne, Ultsch Bernhard, Wichmann Ole, Krämer Alexander, Greiner Wolfgang
Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615 Bielefeld, Germany.
Epidemiological and Statistical Methods Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Cost Eff Resour Alloc. 2017 Sep 4;15:18. doi: 10.1186/s12962-017-0080-9. eCollection 2017.
The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model.
Based on a mathematical model simulating the transmission dynamics and the natural history of HPV infection and associated diseases (cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the epidemiological and economic consequences of HPV vaccination with both the quadrivalent and bivalent vaccines. In our base case analysis, we assessed the cost-effectiveness of vaccinating 12-year-old girls with a 3-dose schedule. In sensitivity analysis, we also evaluated the use of a 2-dose schedule and assessed the impact of vaccinating boys.
From a health care payer perspective, incremental cost-effectiveness ratios (ICERs) of a 3-dose schedule were €34,249 per quality-adjusted life year (QALY) for the bivalent and €14,711 per QALY for the quadrivalent vaccine. Inclusion of indirect costs decreased ICERs by up to 40%. When adopting a health care payer perspective, ICERs of a 2-dose approach decreased to €19,450 per QALY for the bivalent and to €3645 per QALY for the quadrivalent vaccine. From a societal perspective, a 2-dose approach using the quadrivalent vaccine was a cost-saving strategy while using the bivalent vaccine resulted in an ICER of €13,248 per QALY. Irrespective of the perspective adopted, additional vaccination of boys resulted in ICERs exceeding €50,000 per QALY, except for scenarios with low coverage (20%) in girls.
Our model results suggest that routine HPV vaccination of 12-year-old girls with three doses is likely to be cost-effective in Germany. Due to the additional impact on genital warts, the quadrivalent vaccine appeared to be more cost-effective than the bivalent vaccine. A 2-dose schedule of the quadrivalent vaccine might even lead to cost savings when adopting a societal perspective. The cost-effectiveness of additional vaccination of boys was highly dependent on the coverage in girls.
本研究旨在使用动态传播模型评估在德国现行宫颈癌筛查计划基础上接种人乳头瘤病毒(HPV)疫苗的成本效益。
基于一个模拟HPV感染及相关疾病(宫颈上皮内瘤变、宫颈癌和尖锐湿疣)传播动态及自然史的数学模型,我们估算了四价和二价疫苗接种HPV疫苗的流行病学和经济后果。在我们的基础病例分析中,我们评估了按3剂次程序为12岁女孩接种疫苗的成本效益。在敏感性分析中,我们还评估了2剂次程序的使用情况,并评估了为男孩接种疫苗的影响。
从医疗保健支付方的角度来看,二价疫苗3剂次程序的增量成本效益比(ICER)为每质量调整生命年(QALY)34,249欧元,四价疫苗为每QALY 14,711欧元。纳入间接成本使ICER降低了40%。从医疗保健支付方的角度来看,二价疫苗2剂次程序的ICER降至每QALY 19,450欧元,四价疫苗降至每QALY 3645欧元。从社会角度来看,使用四价疫苗的2剂次程序是一种节省成本的策略,而使用二价疫苗的ICER为每QALY 13,248欧元。无论采用哪种角度,为男孩额外接种疫苗的ICER均超过每QALY 50,000欧元,但女孩覆盖率较低(20%)的情况除外。
我们的模型结果表明,在德国为12岁女孩常规接种3剂次HPV疫苗可能具有成本效益。由于对尖锐湿疣有额外影响,四价疫苗似乎比二价疫苗更具成本效益。从社会角度来看,四价疫苗的2剂次程序甚至可能节省成本。为男孩额外接种疫苗的成本效益高度依赖于女孩的覆盖率。